Ivermectin is one of medicine's genuine success stories, a compound drawn from a soil bacterium that has protected millions of people from parasitic blindness and disabling infection. But its safe and effective use depends on a principle that is easy to state and easy to overlook: the dose is calculated in micrograms per kilogram of body weight, not counted out in tablets. This article explains why weight-based dosing matters, what the clinical evidence actually supports, where tablet-counting shortcuts break down, and what responsible use looks like for a patient and family working with their own physician.

A Compound Born of the Soil, Dosed by the Body

Ivermectin descends from avermectin, a family of compounds isolated from Streptomyces avermitilis, a bacterium found in a soil sample collected near a golf course in Japan. Satoshi Ōmura identified the organism, and William Campbell, working at Merck, helped develop it into a medicine effective against parasitic worms. The two shared part of the 2015 Nobel Prize in Physiology or Medicine for this work. It is worth pausing on that origin: a molecule quietly present in ordinary soil turned out to interrupt a disease, onchocerciasis, or river blindness, that had blinded and disfigured people in some of the poorest rural regions of Africa and Latin America for generations. It is a reminder that the created world contains resources whose value was hidden until careful science uncovered them, and that every person affected by that disease, however remote the village, was worth the decades of research it took to help them.

The human dosing standard was not guessed at. Randomized field trials conducted in the late 1980s in West Africa and Latin America, published in journals including The Lancet, established that a single dose of approximately 150 micrograms per kilogram cleared the microfilariae responsible for onchocerciasis with an acceptable safety profile. Later studies refined dosing for strongyloidiasis, an intestinal roundworm infection, to approximately 200 micrograms per kilogram. Those numbers, expressed per kilogram of body weight, are the actual medical dose. The familiar 3-milligram tablet, and the weight-band charts that translate a person's weight into a number of tablets, are a convenience built on top of that underlying calculation, not a replacement for it.

Why Weight, and Not the Pill, Determines the Dose

Pharmacology explains why body size, rather than a fixed pill count, governs the correct amount of a drug. Ivermectin is lipophilic, meaning it distributes readily into fatty tissue, and its volume of distribution in the body scales with a person's overall size and composition. The liver's capacity to metabolize it, largely through the CYP3A4 enzyme pathway, and the rate at which it is eventually cleared, mostly through the feces, also scale roughly with body mass. Its half-life in the body is commonly cited at around 18 hours. All of this means that the plasma concentration achieved by a given number of milligrams depends heavily on how large the person taking it is. A dose that clears parasites effectively in a 70-kilogram adult may be subtherapeutic in a 100-kilogram adult and needlessly high, relative to what is required, in a 25-kilogram child.

This is why the FDA-approved labeling for oral ivermectin presents dosing as weight bands that approximate the mg/kg target, not as a flat "one tablet fits all" instruction. At the lower and upper edges of any weight band, rounding to a whole number of 3-milligram tablets introduces a small margin of imprecision that clinicians generally accept as clinically unimportant within the studied range. But the moment a patient's weight sits well outside that range, or a caregiver estimates rather than weighs, the underlying mg/kg target can be missed by a meaningful amount. It is also worth being honest about a real gap in the evidence: dosing guidance for patients at the extremes of body weight, particularly significant obesity, rests on a thinner evidence base than the dosing established for typical adult weights, and this is a case where individualized clinical judgment matters more than a printed chart.

The Dosing Pole: A Field Solution Rooted in the Same Principle

Nowhere is the commitment to weight-based dosing clearer than in the mass drug administration campaigns that have distributed ivermectin across sub-Saharan Africa and parts of Latin America since 1987 through the Mectizan Donation Program. In villages without clinical scales, community health workers use a simple measuring pole marked with height ranges, because height correlates closely enough with weight to approximate the correct mg/kg dose without a scale. It is a low-tech solution, but it exists precisely because public health authorities would not settle for handing out a uniform dose to every adult regardless of size. Getting the dose wrong in either direction carries a cost: too little risks incomplete treatment and, over repeated mass campaigns, the possibility of encouraging drug resistance in the parasite population; too much increases the risk of side effects without added benefit. The dosing pole is a practical expression of the same principle that governs a pharmacy dispensing tablets in a Western clinic: the medicine is dosed to the person, not the package.

Where Tablet-Counting Fails: Veterinary Formulations

The clearest illustration of what goes wrong when people abandon mg/kg calculation in favor of guesswork comes from veterinary ivermectin products. Formulations made for horses, cattle, and other livestock are manufactured at concentrations designed for animals weighing several hundred kilograms, dosed by a farmer using a weight-marked syringe or paste tube calibrated for that animal's size, not a person's. During 2021, the FDA issued a public warning against using animal ivermectin products in humans, and the CDC's Health Alert Network, along with poison control centers around the country, reported a rise in calls related to ivermectin exposure, a substantial share of them tied to people self-dosing with livestock formulations rather than calculating an actual milligram-per-kilogram human dose. This was not a controversy about ivermectin's known safety profile at its studied human dose; it was, more simply, a matter of overdose arithmetic. Estimating "a few clicks of the plunger" or "a portion of the tube" bears no reliable relationship to milligrams per kilogram, and the concentration difference between an equine paste and a human tablet is large enough that small estimation errors translate into large dosing errors.

The clinical picture of ivermectin toxicity is dose-dependent and explains why this matters. Under normal circumstances, a transporter protein called P-glycoprotein helps keep ivermectin out of the central nervous system by pumping it back across the blood-brain barrier. At high enough doses, or when that transport system is overwhelmed or impaired, ivermectin can accumulate in the brain and produce dizziness, tremor, loss of coordination, low blood pressure, seizures, and in severe cases coma. These are not typical findings at approved human doses; they are described in case reports and toxicology literature associated with substantial overdose, which is exactly the scenario that guesswork dosing from animal products can produce.

What the COVID-19 Trials Actually Tested

Ivermectin is not FDA-approved for the prevention or treatment of COVID-19, and that should be stated plainly. It was studied for that purpose in legitimate randomized controlled trials, and the results are worth summarizing honestly. The TOGETHER trial, a platform trial run through a collaboration involving McMaster University and Brazilian research sites, published in the New England Journal of Medicine in 2022, tested ivermectin at standard human weight-based dosing in outpatients with COVID-19 and found no significant reduction in hospitalization or emergency visits compared with placebo. ACTIV-6, a National Institutes of Health-funded platform trial published in JAMA in 2022, tested ivermectin at doses somewhat higher than earlier trials, still calculated according to standard human mg/kg pharmacology, and again found no significant improvement in time to recovery among outpatients with mild-to-moderate illness. These are randomized trials, the strongest type of clinical evidence available, and they should be distinguished clearly from the in vitro laboratory studies that first suggested antiviral activity against the virus in cell culture at concentrations far higher than what oral dosing achieves in the human body. The gap between a laboratory dish and a living patient is exactly the gap that mg/kg dosing is designed to bridge, and in this case the human trials did not confirm the promise of the cell-culture data.

What is relevant to this article's theme is that even in trials testing a repurposed use, the research doses were calculated by body weight according to established human pharmacology. The confusion and occasional harm arose specifically when members of the public tried to replicate that idea outside clinical and pharmacy oversight, using non-human products and rough estimation instead of an actual calculation.

Practical Stewardship for Patients and Families

None of this is complicated once the principle is clear, and applying it responsibly is well within the reach of any attentive patient or parent working with their own physician and pharmacist.

This is what informed consent and medical freedom look like in practice: not an instruction to avoid medical guidance, but the confidence to ask a physician the right question and understand the answer. A family that takes seriously its duty to care for its own is well served by knowing that a good dose is a calculated one.

Key takeaway: Ivermectin's safety and effectiveness depend on dosing calculated in micrograms per kilogram of actual body weight, verified with a physician or pharmacist, never approximated from tablet counts or animal formulations.